The Dynamics of Death in Prostate Cancer

被引:7
作者
Vollmer, Robin T. [1 ,2 ]
机构
[1] VA Med Ctr, Dept Lab Med, Durham, NC 27705 USA
[2] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
关键词
Hazard function; Histology; Prostate cancer; Survival; HAZARD FUNCTION; ANTIGEN; OVERDIAGNOSIS; MORTALITY; BIOPSIES; CUTOFFS; TUMOR;
D O I
10.1309/AJCPJK9V9LUMUETV
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The hazard function provides the instantaneous probability of death (or other key endpoint) at various times after diagnosis. Unlike the survival curve, the hazard function illustrates graphically or through calculations when deaths are common or uncommon. In this study, hazard functions were derived for prostate cancer by using survival data on large numbers of patients with prostate cancer with data in the Surveillance, Epidemiology and End Results (SEER) database. The results demonstrate a form of prostate cancer that rapidly evolves to cause death within 5 years, and this form of tumor is only partly identified by routine prognostic variables such as serum prostate-specific antigen (PSA) level, histologic grade, and quantity of tumor. The results also validate the presence of a reservoir of nonfatal prostate cancers that have increased rapidly during the PSA era, and they demonstrate that the incidence of fatal prostate cancers has declined.
引用
收藏
页码:957 / 962
页数:6
相关论文
共 28 条
[1]  
ABLIN RJ, 1970, J REPROD FERTIL, V22, P573
[2]   Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].
Andriole, Gerald L. ;
Grubb, Robert L., III ;
Buys, Saundra S. ;
Chia, David ;
Church, Timothy R. ;
Fouad, Mona N. ;
Gelmann, Edward P. ;
Kvale, Paul A. ;
Reding, Douglas J. ;
Weissfeld, Joel L. ;
Yokochi, Lance A. ;
Crawford, E. David ;
O'Brien, Barbara ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hayes, Richard B. ;
Kramer, Barnett S. ;
Izmirlian, Grant ;
Miller, Anthony B. ;
Pinsky, Paul F. ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319
[3]   SERUM PROSTATE-SPECIFIC ANTIGEN - THE MOST USEFUL TUMOR-MARKER [J].
ANDRIOLE, GL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1205-1207
[4]  
[Anonymous], REGRESSION MODELING
[5]  
[Anonymous], HUM PATHOL
[6]   Lowering PSA cutoffs to enhance detection of curable prostate cancer [J].
Catalona, WJ ;
Ramos, CG ;
Carvalhal, GF ;
Yan, Y .
UROLOGY, 2000, 55 (06) :791-795
[7]   COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE-SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE-CANCER - RESULTS OF A MULTICENTER CLINICAL-TRIAL OF 6,630 MEN [J].
CATALONA, WJ ;
RICHIE, JP ;
AHMANN, FR ;
HUDSON, MA ;
SCARDINO, PT ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 151 (05) :1283-1290
[8]   A MARKOV MODEL OF THE NATURAL-HISTORY OF PROSTATE-CANCER [J].
COWEN, ME ;
CHARTRAND, M ;
WEITZEL, WF .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (01) :3-21
[9]   Overdiagnosis in early detection programs [J].
Davidov, O ;
Zelen, M .
BIOSTATISTICS, 2004, 5 (04) :603-613
[10]   Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].
Draisma, G ;
Boer, R ;
Otto, SJ ;
van der Cruijsen, IW ;
Damhuis, RAM ;
Schröder, FH ;
de Koning, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878